Sign in

Simmaron Research Foundation

@simmaronresearch.bsky.social
73 followers 104 following 33 posts

501c3 dedicated to discovering treatments for ME/CFS, LongCovid and IACCs, collaborating with expert clinicians and scientists.

PostsRepliesMedia
Simmaron Research Foundation @simmaronresearch.bsky.social · 21/09/2026
We are proud to announce that we have achieved an R-01 grant from NIH. This prestigious award is a huge feat for ME research and highlights the work that Simmaron has been doing to uncover mechanistic drivers in #ME and #LongCovid that can lead to treatment options for patients. Congrats team!
052
Simmaron Research Foundation @simmaronresearch.bsky.social · 21/09/2026
Our rapamycin studies are very promising, yet we know the findings need to be confirmed in a placebo-controlled trial. Listen to Dr. Gunnar Gottschalk explain why we studied mechanisms of rapamycin in responders, and how a random controlled trial can cut through heterogeneity in #ME. #PEM #Longcovid
010
Simmaron Research Foundation @simmaronresearch.bsky.social · 12/09/2026
The recently published findings from Phase II of our rapamycin treatment trial describe 3 pathways that are disrupted in #ME patients and are improved through treatment with Rapamycin. We summarize those findings in a series of updates, starting with mitochondrial dysfunction. bit.ly/4xhafmi
010
Simmaron Research Foundation @simmaronresearch.bsky.social · 08/09/2026
Interested in finding out more about our #ME and #LongCovid research and upcoming work? Sign up for email updates! www.simmaronresearch.com/signup #MECFS #POTS
033
Simmaron Research Foundation @simmaronresearch.bsky.social · 29/08/2026
Dr. Avik Roy summarizes our first scientific aim with Phase II of the rapamycin trial. Take a listen for yourself and find out why this trial is different from past endeavours.
010
Simmaron Research Foundation @simmaronresearch.bsky.social · 29/08/2026
Does Rapamycin improve mitochondrial energy metabolism in ME/CFS patients? Listen to Dr. Avik Roy explain the importance of mitochondrial energy and the impact found in the Rapamycin trial.
010
Simmaron Research Foundation @simmaronresearch.bsky.social · 09/08/2026
Our decentralized #rapamycin trial allowed #SevereME patients to participate. When necessary, we reduced blood draw volumes and made every effort to help patients complete surveys. In a few cases, this meant conducting surveys over the phone. We all need new models. #ME #MECFS #Longcovid
030
Simmaron Research Foundation @simmaronresearch.bsky.social · 23/07/2026
A Simmaron short explaining how our #rapamycin observational trial is filling unmet needs in #MECFS treatment trials. @ggottschalk.bsky.social @avikroy.bsky.social @AgelessRX #POTS #Longcovid
062
Simmaron Research Foundation @simmaronresearch.bsky.social · 18/07/2026
Here's a short summary of our newest Jnl of Translational Medicine pub sharing results of Ph 2 of our rapamycin trial & showing how rapamycin may tie three converging threads of metabolic impairment together in #MECFS. #Longcovid #POTS simmaronresearch.salsalabs.org/jtrrapaph2pub
0124
Simmaron Research Foundation @simmaronresearch.bsky.social · 16/07/2026
Rapamycin may tie three converging threads of metabolic impairment together in #MECFS. Here's a replay of Simmaron's team detailing new findings from Ph 2 of our rapamycin trial, in case you missed it! TY Solve for hosting us! #LongCovid #POTS www.youtube.com/watch?v=oJnU...
085
Simmaron Research Foundation @simmaronresearch.bsky.social · 14/07/2026
2 hours to go! Register and hear our team detail findings published yesterday in Journal of Translational Medicine on Ph II of our rapamycin trial.
010
Simmaron Research Foundation @simmaronresearch.bsky.social · 13/07/2026
Thank you to every participant, clinician, collaborator, donor, and funding agency who made this transformational work possible. As a non-profit, we can't do it without you! #MECFS #longcovid #Rapamycin #ClinicalTrials #Autophagy
021
Simmaron Research Foundation @simmaronresearch.bsky.social · 13/07/2026
We believe the future of ME/CFS treatment lies in biomarker-guided precision medicine rather than one-size-fits-all therapies. A placebo-controlled trial and development of a diagnostic to help predict responders are the next steps!
131
Simmaron Research Foundation @simmaronresearch.bsky.social · 13/07/2026
Importantly, the study demonstrates that decentralized clinical trials can successfully enroll and follow patients across the United States while maintaining rigorous scientific standards.
120
Simmaron Research Foundation @simmaronresearch.bsky.social · 13/07/2026
Our findings extend beyond clinical symptom improvement, which itself is so important to patients! We also identified molecular changes involving autophagy and purine metabolism that may help explain why some patients improve. link.springer.com/article/10.1...
link.springer.com
Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in...
Background and rationale In our ongoing phase II observational pilot trial, the compounded formulation of low-dose rapamycin significantly reduced fatigue-related clinical symptoms in ME/CFS subjects....
120
Simmaron Research Foundation @simmaronresearch.bsky.social · 13/07/2026
We're excited to announce Journal of Translation Medicine published findings from Phase II of our clinical trial evaluating low-dose rapamycin in people with #MECFS. This work builds upon years of laboratory research into mTOR signaling, autophagy, and mitochondrial dysfunction. 🧵
153
Simmaron Research Foundation @simmaronresearch.bsky.social · 03/07/2026
@solveme.bsky.social Our Simmaron science team has upcoming news you want to hear! Sign up for updates, and help keep us out of your spam folder. #ME #MECFS #LongCovid #PEM www.simmaronresearch.com/signup
072
Reposted by Simmaron Research Foundation
Solve M.E. @solveme.bsky.social · 30/06/2026
Register today for our free webinar, “Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS,” with the Simmaron Research team. Tues. July 14, @ 3:00 pm PT / 6:00 pm ET. ow.ly/jsrZ50Zg3CA
Virtual panel announcement for a July 14 webinar on repurposing rapamycin for ME/CFS featuring four experts from Simmaron Research and Solve M.E. President & CEO Emily Taylor.
093
Simmaron Research Foundation @simmaronresearch.bsky.social · 25/06/2026
Autophagy is how cells clean up damaged components and maintain energy balance. When this process fails, things go wrong. Follow our posts over the next few days as we explain what we learned. link.springer.com/article/10.1...
link.springer.com
Genetic depletion of the early autophagy protein ATG13 impairs mitochondrial energy metabolism, augments oxidative stress, induces the polarization of macrophages to the M1 inflammatory mode, and comp...
Objective M1 macrophage activation is crucial in chronic inflammatory diseases, yet its molecular mechanism is unclear. Results Our study showed that hemizygous deletion of the early autophagy gene at...
030
Simmaron Research Foundation @simmaronresearch.bsky.social · 25/06/2026
What if a single gene involved in cellular recycling could help explain symptoms of #MECFS and #LongCOVID? Our findings published in Inflammation Research this Spring dig into that question. This study focused on ATG13, a key regulator of autophagy, which we found increased in a subset of patients.
Chart explaining the loss of autophagy through mitochondria dysfunction, inflammatory microphages known as M1, and Myelin damage that leads to Muscle Impairment and Nerve Dysfunction.
160
Simmaron Research Foundation @simmaronresearch.bsky.social · 21/04/2026
Why placebo trials for #MECFS & #LongCovid? It’s how drugs get approved, and we have none. Placebo trials change medicine. We'll compare RAPAMYCIN with placebo, and all will receive treatment. We seek to prove which subset responds and change medicine, finally. www.simmaronresearch.com/donate
010
Reposted by Simmaron Research Foundation
Solve M.E. @solveme.bsky.social · 15/04/2026
Watch! Dr. Avik Roy & Dr. Gunnar Gottschalk of Simmaron Research Foundation share how six years of work on the molecular mechanisms of #MECFS has led to one of the only ongoing clinical trials specifically designed around a defined biological target. youtu.be/OMmjcTKxivU #MEAwarenessHour
Banner for ME/CFS Q&A series featuring a compass on wood and researchers Dr. Gunnar Gottschalk and Dr. Avik Roy from Simmaron Research Institute.
121
Simmaron Research Foundation @simmaronresearch.bsky.social · 18/04/2026
Thank you Solve for spotlighting and supporting our treatment-focused science! You can sign up for periodic updates from our non-profit here: www.simmaronresearch.com/signup
simmaronresearch.com
Sign up for our email list — Simmaron Research
000
Simmaron Research Foundation @simmaronresearch.bsky.social · 04/04/2026
#ME & #LongCovid have no FDA approval, no successful placebo-controlled trial, no accepted biomarker. Our placebo-controlled rapamycin trial is a strategic opportunity for change. Read how testing biomarkers with treatment holds so much promise: simmaronresearch.salsalabs.org/placebotrial #MECFS
010
Simmaron Research Foundation @simmaronresearch.bsky.social · 02/04/2026
Why low-dose rapamycin? It regulates mTOR & autophagy, pathways that may be disrupted in #MECFS & #LongCOVID. Our placebo-controlled trial measures biomarkers, immune signaling, and metabolics to learn why some improve, and who is likely to. Help us prove it. DONATE: www.simmaronresearch.com/donate
153
Simmaron Research Foundation @simmaronresearch.bsky.social · 29/03/2026
Our placebo-controlled trial will pay for the costs of rapamycin, placebo, safety tests, biomarker tests and clinical work, to ease patient burden & so results aren’t influenced by costs. A generous donor will double your gift! Help prove treatments for #ME #LongCovid www.simmaronresearch.com/donate
030
Simmaron Research Foundation @simmaronresearch.bsky.social · 25/03/2026
5️⃣ Your support can help generate the evidence needed for evidence-based treatment. Your gift will be matched by a generous donor! Donate today. www.simmaronresearch.com/donate
000
Simmaron Research Foundation @simmaronresearch.bsky.social · 25/03/2026
4️⃣ Now we are launching a double-blind placebo-controlled trial embedded within our Phase II study to test these findings rigorously and develop a biomarker to help predict responders. This is brand new for our disease. www.simmaronresearch.com/donate 3/4
110
Simmaron Research Foundation @simmaronresearch.bsky.social · 25/03/2026
3️⃣ Early observational data suggests some patients experience improvements from rapamycin in fatigue and post-exertional malaise. We published those results in the high impact Journal of Translational Medicine: link.springer.com/article/10.1... 2/4
link.springer.com
Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study - Journal of Translational Medicine
Background mTOR activation is associated with chronic inflammation in ME/CFS. Previous studies have shown that sustained mTOR activation may cause chronic muscle fatigue by inhibiting ATG13-mediated a...
110
Simmaron Research Foundation @simmaronresearch.bsky.social · 25/03/2026
1️⃣ #MECFS and #LongCOVID affect millions worldwide — yet no @FDA approved treatment exists. 2️⃣ Our team at Simmaron Research is studying low-dose rapamycin, a drug that regulates cellular pathways involved in inflammation and autophagy. Thread 🧵1/4
141
Simmaron Research Foundation @simmaronresearch.bsky.social · 22/03/2026
ATG13 2022, our initial publication finding pATG13 in a subset of #ME patients: www.sciencedirect.com/science/arti... 4/4
sciencedirect.com
Elevated ATG13 in serum of patients with ME/CFS stimulates oxidative stress response in microglial cells via activation of receptor for advanced glycation end products (RAGE)
Myalgic Encephalomyelitis, also known as Chronic Fatigue Syndrome (ME/CFS), is a multisystem illness characterized by extreme muscle fatigue associate…
000
Simmaron Research Foundation @simmaronresearch.bsky.social · 22/03/2026
Mouse Model 2025, demonstrating PEM in animal model resulting from pATG13 (inactive): link.springer.com/article/10.1... 3/4
link.springer.com
Inactivation of ATG13 stimulates chronic demyelinating pathologies in muscle-serving nerves and spinal cord - Immunologic Research
Abstract Chronic muscle fatigue is a condition characterized by debilitating muscle weakness and pain. Based on our recent finding to study the potential effect of mTOR on ATG13 inactivation in chroni...
100
Simmaron Research Foundation @simmaronresearch.bsky.social · 22/03/2026
Other pub links here: Our Inflammation Research 2026, describing mechanisms of PEM and new actors in inflammation following autophagy disruption: link.springer.com/article/10.1... 2/4
link.springer.com
Genetic depletion of the early autophagy protein ATG13 impairs mitochondrial energy metabolism, augments oxidative stress, induces the polarization of macrophages to the M1 inflammatory mode, and comp...
Objective M1 macrophage activation is crucial in chronic inflammatory diseases, yet its molecular mechanism is unclear. Results Our study showed that hemizygous deletion of the early autophagy gene at...
100
Simmaron Research Foundation @simmaronresearch.bsky.social · 22/03/2026
Our new placebo-controlled rapamycin trial is based on 4 publications of our work on mechanisms & biomarkers disrupting autophagy in a subset of #MECFS & #Longcovid. Phase 1 of our treatment & biomarker trial was published in Jnl of Translational Medicine: link.springer.com/article/10.1.... 1/4🧵
link.springer.com
Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study - Journal of Translational Medicine
Background mTOR activation is associated with chronic inflammation in ME/CFS. Previous studies have shown that sustained mTOR activation may cause chronic muscle fatigue by inhibiting ATG13-mediated a...
131
Simmaron Research Foundation @simmaronresearch.bsky.social · 21/03/2026
We’re launching a placebo-controlled study of rapamycin for #MECFS and #LongCOVID. Early data from our Phase II trial shows promise — now we must test it under rigorous blinded conditions. Help us make it happen. Donate to support the study. www.simmaronresearch.com/donate #ME #Rapamycin
02611